Case Studies in Hormone Replacement Therapy

By Ross, Brendan S; Ramsey, Leigh Ann; Low, Annette K | Drug Topics, May 15, 2000 | Go to article overview

Case Studies in Hormone Replacement Therapy


Ross, Brendan S; Ramsey, Leigh Ann; Low, Annette K, Drug Topics


Menopause is the cessation of menses that signifies the depletion of ovarian follicle estradiol production. Even as life spans have lengths ened, the median age at the onset of menopause has remained constant at approximately 51 years; thus, the time women spend in a hormone-deficient state is increasing. So, too, are their risks for the detrimental metabolic and physiologic consequences of estrogen depletion.

Early research focused on the benefits of estrogen replacement therapy (ERT) for the relief of vasomotor complaints in perimenopausal women. Study has now shifted to the use of hormone replacement therapy (HRT) in preventing and treating diseases that typically occur decades after menopause. The proven efficacy of ERT to ameliorate symptoms and osteoporosis risks and its potential to reduce rates of cardiovascular disease and dementia have led to recommendations that all postmenopausal women consider using HRT.

The following case studies delineate issues in the contemporary pharmacologic management of menopause based on the results of recently reported clinical trials.

Case study #1

A 50-year-old with hot flushes documented to be perimenopausal by an elevated serum follicle stimulating hormone (FSH) value is fearful of initiating ERT because of a strong family history of breast cancer. What are alternative therapies to relieve her vasomotor symptoms? Why would a synthetic estrogen receptor modulator (SERM) not be an optimal choice?

Only 20% of postmenopausal women ever use HRT. The most frequently cited reason for this underutilization is fear of breast cancer. These fears are fostered by the failure of women, the media, and even physicians to understand risk reporting.

Epidemiologic studies garner relative risk as a sum

An ongoing CE program of

The University of Mississippi School of Pharmacy and DRUG TOPICS many measure of disease frequency. The risk of breast cancer from ERT is not 20%-30%, as commonly reported. This is merely the increased risk of breast cancer in women who receive ERT relative to those who do not:. A more meaningful statistic for clinical decision-making is the excess risk of breast cancer attributable to ERT use.

The association between HRT and breast cancer was the primary focus of a meta-analysis of 51 studies involving 160,000 postmenopausal women. This study revealed that the duration of ERT use is positively correlated with an increased relative risk-a linear increased risk of breast cancer of 2.3% each year,. A recently published report confirmed that these data could be integrated with incident rates from the National Cancer Institute to yield attributable risks for women considering ERT. In a population of 50-yearold women, 2.5 will develop breast cancer in 10 years. If the relative risk of breast cancer is increased 23% by ERT use over that period, then less than one additional woman would get a breast cancer she would otherwise avoid if she were not to take estrogen (i.e., a 2.5 incident rate multiplied by a 23% relative risk yields an attributable risk of 0.58). For a 50-year-old considering ERT, an attributable risk of approximately 0.6 means a less than a one-in-100 chance of incurring an estrogen-induced breast cancer over 10 years. Stated yet another way, approximately 97% of 50-year-old women using HRT for 10 years will not bet breast cancer. When understood more clearly, ERT associated cancer risks are less alarming.

The impact of HRT on other cancers is less clear. Clinical trials reveal an increased incidence of endometrial hyperplasia in women treated with unopposed ERT. When estrogen is used with a progestin, the increased risk of this precursor to endometrial cancer is alleviated (Table 1). Epidemiologic evidence of a protective effect of HRT on colorectal cancer is conflicting. The large-scale Women's Health Initiative (WHI), a randomized, controlled trial of the concurrent use of conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) in 8,000 women, should clarify the nature and degree of HRT cancer risks when it is reported in 2002.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Case Studies in Hormone Replacement Therapy
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.